Fig. 5: Mutations of E and NS2A from 17D attenuate YFVs in vivo. | Nature Microbiology

Fig. 5: Mutations of E and NS2A from 17D attenuate YFVs in vivo.

From: Amino acid changes in two viral proteins drive attenuation of the yellow fever 17D vaccine

Fig. 5

a, Workflow of mouse challenge experiments. Illustration generated with figures from the NIAID NIH BIOART source. b,c, Survival of Ifnar1−/− mice infected with 17D (n = 16) or 17D chimaeras (n = 8 each) (b) and Dakar (n = 8) or Dakar chimaeras (n = 8 each) (c). Mice were monitored daily for 15 days for clinical signs. d, Representative images of liver sections stained with DAPI, anti-human FAH, anti-YFV-NS4B and anti-ISG15 at 3 days post infection (n = 3 mice). Scale bar, 100 μm. e, Correlation between NS4B and ISG15 expression in human (FAH-positive) cells. Scatterplot showing the percentage of NS4B+/FAH+ cells (x axis) versus ISG15+/FAH+ cells (y axis) of individual samples. Each dot represents an individual sample, colour-coded by experimental group. Quantification was performed across the whole slide section (n = 3). Asibi or Dakar-[17D-Ens], 17D E segment with only non-synonymous mutations compared to Asibi; 17D-[Asibi-Ens], Asibi E segment with only non-synonymous mutations compared to 17D. All other chimaeras include synonymous and non-synonymous mutations in the indicated genomic areas. log-rank (Mantel–Cox) test for pairwise comparison to 17D (b) or Dakar (c) as coloured.

Source data

Back to article page